Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
4
Bullish
6
Bearish
36
Neutral
4
Bullish
6
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Sheel Biotech Limited is an integrated agri‑horticulture company providing tissue culture planting material, protected cultivation (greenhouse, aeroponic, hydroponic), packhouse and cold‑chain infrastructure, organic adoption and FPO services, and premium landscaping; its business model spans genetics, farm execution and market access across institutional and retail channels.
Financially the company reported revenue of ₹110.02 crores in FY26, up from ₹101.75 crores in FY25, with gross margin improving to 38.24% and EBITDA margin at 15.45%; PAT rose to ₹11.76 crores in FY26 despite EPS dilution following a material equity issuance tied to recent capital raises.
Sheel has pivoted strategically into high‑value berries — blueberry, strawberry and raspberry — leveraging 30+ years of tissue culture expertise, exclusive breeder partnerships (including Spain’s Cuna de Platero) and an existing protected‑cultivation and cold‑chain footprint to pursue premium domestic and export markets.
The company operates a broad institutional and farmer network: 50 FPOs, execution of organic programs across 15 states covering 1,98,502 farmers and 1,41,709 hectares, and marquee clients including DRDO, ICAR, Amul and leading hotel chains, providing both demand channels and government‑backed program access.
Balance sheet dynamics show active capex and liquidity improvement — capital work‑in‑progress appeared in FY26 and cash increased, while long‑term borrowings declined; however trade receivables remain elevated and inventory reduced, implying working‑capital management will be critical during scale‑up.
Industrial Manufacturing
Industrial Products
115 Cr
Low Risk
9.8
44.5
0.3
0.9
81.00
37.80
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
109.00 | 123 Cr | 10.35 | 1.28 | 0.00 | 12.42 | 15.24 | 7.69 | ||
22.60 | 120 Cr | 10.09 | 0.54 | 0.00 | 3.53 | 3.06 | 4.33 | ||
49.99 | 120 Cr | 38.87 | 1.21 | 0.00 | 1.03 | 3.22 | 1.13 | ||
85.61 | 117 Cr | 10.61 | 1.50 | 0.00 | 14.11 | 14.99 | 9.49 | ||
56.65 | 115 Cr | 9.80 | 0.91 | 0.00 | 9.26 | 11.72 | 8.07 | ||
92.95 | 112 Cr | 13.57 | 1.08 | 0.00 | 8.61 | 11.60 | 2.82 | ||
| Median: 6 Co. | — | 71.13 | 118 Cr | 10.48 | 1.15 | 0.00 | 8.93 | 11.66 | 6.01 |
Sheel Biotech Ltd (SHEEL) is currently trading at 56.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sheel Biotech Limited is an integrated agri‑horticulture company providing tissue culture planting material, protected cultivation (greenhouse, aeroponic, hydroponic), packhouse and cold‑chain infrastructure, organic adoption and FPO services, and premium landscaping; its business model spans genetics, farm execution and market access across institutional and retail channels. Financially the company reported revenue of ₹110.02 crores in FY26, up from ₹101.75 crores in FY25, with gross margin improving to 38.24% and EBITDA margin at 15.45%; PAT rose to ₹11.76 crores in FY26 despite EPS dilution following a material equity issuance tied to recent capital raises. Sheel has pivoted strategically into high‑value berries — blueberry, strawberry and raspberry — leveraging 30+ years of tissue culture expertise, exclusive breeder partnerships (including Spain’s Cuna de Platero) and an existing protected‑cultivation and cold‑chain footprint to pursue premium domestic and export markets. The company operates a broad institutional and farmer network: 50 FPOs, execution of organic programs across 15 states covering 1,98,502 farmers and 1,41,709 hectares, and marquee clients including DRDO, ICAR, Amul and leading hotel chains, providing both demand channels and government‑backed program access. Balance sheet dynamics show active capex and liquidity improvement — capital work‑in‑progress appeared in FY26 and cash increased, while long‑term borrowings declined; however trade receivables remain elevated and inventory reduced, implying working‑capital management will be critical during scale‑up.
Over the past 52 weeks, Sheel Biotech Ltd has traded between a low of ₹37.80 and a high of ₹81.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sheel Biotech Ltd has a market capitalization of approximately 115.30. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sheel Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 9.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 115.30 Cr, Sheel Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sheel Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sheel Biotech Ltd is 9.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The IPO opened on 30 September 2025 and closed on 3 October 2025, with allotment stated for 6 October 2025.
